** Biotech company Humacyte's HUMA.O shares rise ~44.2% to $4.99 premarket
** HUMA, late on Thursday, said the U.S. FDA approved its implant Symvess for patients with extreme blood vessel injury
** The approval was based on clinical tests where Symvess showed high rates of blood flow and low rates of infection
** HUMA says the implant can be used as a channel in patients who need to have their blood flow restored to avoid imminent limb loss
** Up to last close, stock up 21.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。